Robert oversees the sustained growth and diversified revenue strategy for CURE, a drug-development company that creates proprietary dosage forms and delivery systems. CURE has global partnerships in the United States, Canada, Israel and Germany. Robert formerly served as CEO of companies such as InnoZen, Gel Tech and Bio Delivery Technologies and has been involved in the development of several drug-delivery technologies and commercial brand extensions.